A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model

PURPOSE: Currently >50% of high-risk neuroblastoma (NB) patients, despite intensive therapy and initial partial or complete response, develop recurrent NB due to the persistence of minimal residual disease (MRD) that is resistant to conventional antitumor drugs. Indeed, their low therapeutic inde...

Descripción completa

Detalles Bibliográficos
Autores principales: Orienti, Isabella, Nguyen, Ferro, Guan, Peng, Kolla, Venkatadri, Calonghi, Natalia, Farruggia, Giovanna, Chorny, Michael, Brodeur, Garrett M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930389/
https://www.ncbi.nlm.nih.gov/pubmed/31908416
http://dx.doi.org/10.2147/DDDT.S221909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930389/
https://www.ncbi.nlm.nih.gov/pubmed/31908416
http://dx.doi.org/10.2147/DDDT.S221909

Ejemplares similares